Partners, Past & Present

Locus has applied its proprietary pipeline engine to various targets in the collaborations summarized below. Note the diversity of targets which also reflect the broad capability and applications of the Locus technology platform.

• Amgen: Target Undisclosed at Client's Request
• Dow AgroSciences: Anti-Fungal Enzyme
• Eli Lilly: Cancer Kinase Inhibitor Design
• Ono Pharmaceuticals 1: IND Candidate for Undisclosed Kinase Target
• Ono Pharmaceuticals 2: IND Candidate for Undisclosed Kinase Target
• Scios: Cancer Kinase Inhibitor Design
• Speedel Experimenta: Renin Protease Inhibitor Design

In summary, Locus has established a robust and proprietary pipeline engine which has demonstrated significant impact on the efficiency and effectiveness of identifying IND leads which now have reached clinical development. Collaborations with Locus can be also be effectively tailored to the partners needs as required.